Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HER3 inhibitors

Novartis building

Novartis gets US nod for lung cancer relapse therapy Zykadia

Second ALK inhibitor to be approved after Pfizer’s Xalkori

- PMLiVE

NICE rejects Roche’s Kadcyla as “unaffordable”

Cancer drug unable to justify £90,000 price tag

National Institute for Health and Care Excellence NICE logo

NICE backs two cancer drugs

Boehringer’s Giotrif and Janssen’s Velcade given final go-ahead for NHS use

Novartis building

Novartis pays $16bn for GSK’s oncology portfolio

Swiss company strikes series of deals, including one to step away from vaccines

- PMLiVE

Lilly’s stomach cancer drug cleared by FDA

Cyramza is tipped to reach blockbuster status depending on approvals

- PMLiVE

BioAlliance and Topotarget merge to focus on rare cancers

French and Danish firms combine to develop orphan oncology drugs

- PMLiVE

UK cancer awards programme launches

QiC Oncology 2014  announced at ABPI Annual Conference

- PMLiVE

Sun Pharma offers $4bn for Ranbaxy

Follows period of manufacturing problems at Daiichi-owned Indian generics company

Roche - Basel

NICE reverses decision to restrict Tarceva access

Roche says “voices of clinicians and patients have been heard”

- PMLiVE

Glioblastomas – a personalised future?

Despite some recent advances treatment remains palliative

EU flag

Europe votes for greater clinical trial transparency

European Parliament passes new EU Clinical Trials Regulation

- PMLiVE

GSK terminates lung cancer vaccine trial

Unable to identify patients who may benefit from MAGE-A3 immunotherapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links